Navigation Links
Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
Date:5/22/2008

NUTLEY, N.J., May 22 /PRNewswire/ -- Roche announced today that a total of 59 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3.

A U.S. abstract to be published in The 2008 ASCO Proceedings I, compares the preclinical efficacy of an investigational, seven-days-on/seven-days-off (7-on/7-off) Xeloda regimen versus the current standard Xeloda dosing of fourteen-days-on/seven-days-off (14-on/7-off) in colorectal cancer. Findings from this study appeared to indicate improved tumor growth inhibition with the 7-on/7-off Xeloda regimen; results support clinical testing of this regimen in colorectal cancer patients. [See 2008 ASCO Proceedings I - An alternative preclinical regimen of capecitabine ( C ) enhances single agent & combination activity in a colorectal cancer xenograft model. (Lead Author: Kenneth Kolinsky)]

Among ex-U.S. Xeloda abstracts being presented, 16 breast cancer and 15 colorectal cancer abstracts highlight Xeloda as the cornerstone of combination treatment. The remaining Xeloda abstracts are also ex-U.S. or sponsored by non-Roche entities.

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significa
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
2. Gene Therapy Provides Vision to People who Were Nearly Blind
3. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
4. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
5. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
6. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
11. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... (Nasdaq: ONXX ) today announced that it will ... will discuss the data presentations surrounding carfilzomib in relapsed ... American Society of Hematology (ASH) Annual Meeting. ,, The ... on Monday, December 7, 2009. The live webcast ...
(Date:12/4/2009)... 4 Shared Imaging, LLC, an independent provider ... programs for hospitals and healthcare providers, is excited ... Accreditation for Ambulatory Health Care, a nationally-recognized, prestigious ... in patient care. Shared Imaging accreditation is system-wide ...
(Date:12/4/2009)... 4 Hospira, Inc. (NYSE: HSP ), ... today announced the launch of its next-generation 50 mL ... and solutions, and now offers a complete size range ... responsible VisIV product. The launch of the 50 mL ...
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Cynosure to Present at the Maxim Group Growth Conference 57944 1Cynosure to Present at the Maxim Group Growth Conference 57944 2New and Interesting PROSTVAC 28TM 29 Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 14203 1New and Interesting PROSTVAC 28TM 29 Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 14203 2New and Interesting PROSTVAC 28TM 29 Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 14203 3Glaucoma Tied to Gene Variants in Blacks 57942 1Glaucoma Tied to Gene Variants in Blacks 57942 2
... 10 Endo Pharmaceuticals (Nasdaq: ENDP ) ... agreements to develop novel treatments for pain and to ... with Harvard University , is based upon a ... Harvard Medical School,s Richard J. Kitz Professor of Anaesthesia ...
... new study published today claiming that multivitamin use by ... mortality fails to take into account important dietary factors ... are regulated by the U.S. Food and Drug Administration ... the February 9 issue of Archives of Internal ...
Other Medicine Technology:Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 3Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association 2
(Date:12/7/2009)... Today the Centers for Disease Control and Prevention (CDC) ... the week was designed to highlight the importance of ... of taking additional steps to keep you and your ... of December, January and beyond. ,, "It,s easy to ... topic of both seasonal and swine flu," said Dr. ...
(Date:12/6/2009)... BROOK, Ill., Dec. 7 The University ... (AMC) members for their achievements in UHC,s Supply ... organizations are noted for modeling best practices in ... http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were determined ... that includes contract portfolio participation and use of ...
(Date:12/6/2009)... future treatments targeting growth factor, researchers say , , ... breast cancer cells from the main tumor to other ... factor known as TGFb, which may prove a promising ... British researchers say. , Previous studies have shown that ... and movement. In this new study, a team from ...
(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...
(Date:12/5/2009)... shown in a phase 1/2 clinical trial that ... of patients newly diagnosed with multiple myeloma, a cancer ... from Dana-Farber Cancer Institute. , Partial responses or better ... with the drug combination in the multi-center study, with ... in the phase 2 population, reports Paul G. Richardson, ...
Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... Provide General Information about Potential Health ConcernsNEWTON, Mass., May ... in the reinvention of how people obtain legal services, ... general information about the potential health hazards of excessive ... consumer product used by an estimated 35 million Americans ...
... colleague Tom Daulton to provide strategic leadership as ... PRAIRIE, Wis., May 5 Devicor Medical Products, ... Executive Vice President, Corporate Development & Strategy. Salkin,s ... the Royal Bank of Scotland plc is highlighted ...
... BERLIN, May 5 Anatomist, Dr. Gunther von Hagens, ... set out three years ago to present the human ... his "HUMAN SAGA" project this week.(Photo: http://www.newscom.com/cgi-bin/prnh/20090505/CG11117 ... hoped to traverse the anatomical landscape left uncharted by ...
... According to a new study led by researchers at ... several factors that contribute to children missing immunization visits. ... presentation at 8:30 a.m. ET on Tuesday, May 5, ... here. , "We know that approximately 20 percent ...
... Will Host ,Day of Dialogue, Online Town Hall Meeting on ... America,s healthcare and long-term services need to undergo a ... seniors and people with disabilities, according to a report released ... report, which will be supported by a nationwide "Day of ...
... Health Care Management WASHINGTON, May 5 ... education organization, announced today that Christine G. Leyden, Senior ... Accreditation Officer for URAC has been recognized as a ... Point magazine. Ms. Leyden will be featured in ...
Other Medicine News:Health News:Sokolove Law Launches Denture Cream Consumer Hotline 2Health News:Jonathan Salkin Named Executive Vice President of Devicor Medical Products 2Health News:Dr. Gunther von Hagens 'HUMAN SAGA' Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life. 2Health News:Why parents miss their children's immunization visits 2Health News:Why parents miss their children's immunization visits 3Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 2Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 3Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 2Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 3
... GE Healthcares new Vivid i ... cardiovascular ultrasound system to provide high-performance, full-featured ... Vivid i addresses one ... access to complete, real-time diagnostic information. ...
The Bio-Quant TROPONIN I test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of cardiac,troponin I (cTnI) in human serum specimens as an aid i...
This advanced digital monitor detects the appearance of an irregular heartbeat during measurement and gives a warning signal with your reading. An irregular heartbeat may cause or indicate cardiovasc...
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
Medicine Products: